Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Shares Outstanding (2016 - 2025)

Spero Therapeutics' Shares Outstanding history spans 10 years, with the latest figure at $56.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 3.34% year-over-year to $56.4 million; the TTM value through Dec 2025 reached $56.4 million, up 3.34%, while the annual FY2025 figure was $56.4 million, 3.34% up from the prior year.
  • Shares Outstanding reached $56.4 million in Q4 2025 per SPRO's latest filing, roughly flat from $56.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $56.4 million in Q4 2025 to a low of $3.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $41.3 million, with a median of $52.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: crashed 84.17% in 2021, then surged 1231.72% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $32.4 million in 2021, then surged by 61.93% to $52.5 million in 2022, then rose by 1.04% to $53.0 million in 2023, then grew by 3.01% to $54.6 million in 2024, then rose by 3.34% to $56.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Shares Outstanding are $56.4 million (Q4 2025), $56.3 million (Q3 2025), and $56.2 million (Q2 2025).